作者
Aphroz Ansari*1, Pushpa Prasad Gupta1, Ramsheela2, Masoom Rahbar3
摘要
Epilepsy is a chronic neurological disorder characterized by recurrent unprovoked seizures and is frequently accompanied by cognitive, behavioral, and psychiatric comorbidities. Despite the availability of numerous antiseizure medications, a substantial proportion of patients remain inadequately controlled, creating a need for therapies with novel mechanisms. Cannabidiol (CBD), a non-intoxicating phytocannabinoid derived from Cannabis sativa, has emerged as a promising antiseizure compound and has subsequently gained regulatory approval for selected developmental and epileptic encephalopathies. This review focuses specifically on preclinical evidence from rat models of epilepsy, emphasizing seizure control, neuroprotection, neuroinflammation, antiepileptogenic effects, pharmacokinetics, and potential mechanisms of action. Studies using pentylenetetrazol (PTZ), pilocarpine, lithium-pilocarpine, kainic acid, audiogenic kindling, and other experimental paradigms demonstrate that CBD can reduce seizure severity, delay seizure onset, decrease seizure burden, and in some models suppress the development or expression of chronic epileptic activity. In rat models of temporal lobe epilepsy, CBD has additionally been associated with reduced neuronal degeneration, modulation of inflammatory cytokines and microglial polarization, changes in PPARγ signaling, and alterations in gut microbiota and metabolomic profiles. Importantly, effects vary with dose, route, treatment timing, model, age, and disease stage. Evidence for genuine antiepileptogenesis remains promising but less established than evidence for acute antiseizure activity. Translation is further complicated by differences in CBD exposure, formulation, metabolism, and pharmacodynamic responses between rodents and humans. Overall, rat studies provide strong mechanistic support for CBD as an antiseizure and potentially neuroprotective agent, but standardized chronic epilepsy protocols, exposure–response studies, sex-balanced designs, rigorous pharmacokinetic–pharmacodynamic characterization, and clinically relevant endpoints are needed to establish its translational value.